186 related articles for article (PubMed ID: 2036663)
41. Are the current IHS guidelines for migraine drug trials being followed?
Hougaard A; Tfelt-Hansen P
J Headache Pain; 2010 Dec; 11(6):457-68. PubMed ID: 20931348
[TBL] [Abstract][Full Text] [Related]
42. Commentary from the Refractory Headache Special Interest Section on defining the pharmacologically intractable headache for clinical trials and clinical practice.
Schulman EA; Lipton R; Peterlin BL; Levin M; Grosberg BM
Headache; 2010 Nov; 50(10):1637-9. PubMed ID: 21198568
[No Abstract] [Full Text] [Related]
43. Guidelines for controlled trials of drugs in migraine: second edition.
Tfelt-Hansen P; Block G; Dahlöf C; Diener HC; Ferrari MD; Goadsby PJ; Guidetti V; Jones B; Lipton RB; Massiou H; Meinert C; Sandrini G; Steiner T; Winter PB;
Cephalalgia; 2000 Nov; 20(9):765-86. PubMed ID: 11167908
[No Abstract] [Full Text] [Related]
44. Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine.
Tassorelli C; Diener HC; Silberstein SD; Dodick DW; Goadsby PJ; Jensen RH; Magis D; Pozo-Rosich P; Yuan H; Martinelli D; Hoek TVD; Deen M; Ashina M; Terwindt GM
Cephalalgia; 2021 Oct; 41(11-12):1135-1151. PubMed ID: 33990161
[TBL] [Abstract][Full Text] [Related]
45. How transparent are migraine clinical trials? Repository of Registered Migraine Trials (RReMiT).
Dufka FL; Dworkin RH; Rowbotham MC
Neurology; 2014 Oct; 83(15):1372-81. PubMed ID: 25194013
[TBL] [Abstract][Full Text] [Related]
46. Migraine treatment in developmental age: guidelines update.
Papetti L; Spalice A; Nicita F; Paolino MC; Castaldo R; Iannetti P; Villa MP; Parisi P
J Headache Pain; 2010 Jun; 11(3):267-76. PubMed ID: 20349201
[TBL] [Abstract][Full Text] [Related]
47. Headache research in 2014: Advancing migraine therapy.
Schulte LH; May A
Lancet Neurol; 2015 Jan; 14(1):6-7. PubMed ID: 25496881
[No Abstract] [Full Text] [Related]
48. Controlled trials in pediatric migraine: crossover versus parallel group.
Evers S
Curr Pain Headache Rep; 2007 Jun; 11(3):241-4. PubMed ID: 17504653
[TBL] [Abstract][Full Text] [Related]
49. Endpoints to evaluate efficacy of symptomatic drugs in migraine: what do patients want?
Pietrini U; De Luca M; Del Bene E
Headache; 2002 Oct; 42(9):948-9. PubMed ID: 12390628
[No Abstract] [Full Text] [Related]
50. Chenodeoxycholic acid in the prevention of migraine.
Lévy VG; Nusinovici V; Rosner D; Darnis F
N Engl J Med; 1978 Mar; 298(11):630. PubMed ID: 342958
[No Abstract] [Full Text] [Related]
51. Clinical trials in migraine: parallel versus crossover studies.
Kunkel RS
Neuroepidemiology; 1987; 6(4):209-13. PubMed ID: 3683715
[TBL] [Abstract][Full Text] [Related]
52. What Constitutes an "Adequate" Trial in Migraine Prevention?
Smith JH; Schwedt TJ
Curr Pain Headache Rep; 2015 Nov; 19(11):52. PubMed ID: 26362764
[TBL] [Abstract][Full Text] [Related]
53. Migraine: preventive treatment.
Mattsson P
Cephalalgia; 2004 Oct; 24(10):908; author reply 908-9. PubMed ID: 15377326
[No Abstract] [Full Text] [Related]
54. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards subcommittee of the American Academy of Neurology and the American Headache Society.
Tfelt-Hansen PC
Neurology; 2013 Feb; 80(9):869-70. PubMed ID: 23439705
[TBL] [Abstract][Full Text] [Related]
55. Dipyridamole in migraine.
Hawkes CH
Lancet; 1978 Jul; 2(8081):153. PubMed ID: 78349
[No Abstract] [Full Text] [Related]
56. Selection of patients--critical aspects.
Diamond S; Solomon GD; Freitag FG; Mehta N
Neuroepidemiology; 1987; 6(4):172-7. PubMed ID: 3317097
[TBL] [Abstract][Full Text] [Related]
57. Prospective study designs in outcomes research: the case of migraine.
Rothermich EA; Brod MI; Schonfeld WH; Rowland CR; Gomez-Mancilla B
Pharmacoeconomics; 2002; 20(11):715-25. PubMed ID: 12201791
[TBL] [Abstract][Full Text] [Related]
58. [Recommendations for prophylactic treatment of migraine: Consensus of the Sociedade Brasileira de Cefaléia].
Brasilian Headache Society
Arq Neuropsiquiatr; 2002 Mar; 60(1):159-69. PubMed ID: 11965429
[TBL] [Abstract][Full Text] [Related]
59. Transparent Reporting of Evaluations with Nonrandomized Designs (TREND).
Vlahov D
J Urban Health; 2004 Jun; 81(2):163-4. PubMed ID: 15136648
[No Abstract] [Full Text] [Related]
60. WITHDRAWN: Drugs for preventing migraine headaches in children.
Victor S; Ryan S
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD002761. PubMed ID: 25019292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
